Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 8/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 6/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18859556 | 0.92 | TNKS (0.40) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL22273914 | 0.92 | LIMK1 (0.39) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL24280853 | 0.91 | MEN1 (0.36) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL24280895 | 0.89 | MEN1 (0.38) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL24280187 | 0.88 | MEN1 (0.39) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL22273906 | 0.87 | LIMK1 (0.41) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL22273920 | 0.86 | MEN1 (0.41) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL24280894 | 0.84 | MEN1 (0.39) | TNKSTNKS2LIMK1PIM1PIM2 | |
| SCHEMBL18806050 | 0.84 | ALOX5 (0.53) | TNKSTNKS2LIMK1ALOX5PIM1 | |
| SCHEMBL22273720 | 0.84 | MEN1 (0.38) | TNKSTNKS2LIMK1ALOX5PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10644244-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-05-18 | — | — | US | disclosed |
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, CRY2, CYBA | TNKS 1638/4885TNKS2 1814/4885LIMK1 595/4885 |
| US-10644244-B2 | Heterocyclic compound and organic light emitting device using same | CRY1, CRY2, CYBA | TNKS 1638/4885TNKS2 1814/4885LIMK1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.